These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
407 related articles for article (PubMed ID: 9813200)
1. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Hevey M; Negley D; Pushko P; Smith J; Schmaljohn A Virology; 1998 Nov; 251(1):28-37. PubMed ID: 9813200 [TBL] [Abstract][Full Text] [Related]
2. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Pushko P; Parker M; Ludwig GV; Davis NL; Johnston RE; Smith JF Virology; 1997 Dec; 239(2):389-401. PubMed ID: 9434729 [TBL] [Abstract][Full Text] [Related]
3. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Swenson DL; Warfield KL; Larsen T; Alves DA; Coberley SS; Bavari S Expert Rev Vaccines; 2008 May; 7(4):417-29. PubMed ID: 18444889 [TBL] [Abstract][Full Text] [Related]
4. Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice. Lee JS; Groebner JL; Hadjipanayis AG; Negley DL; Schmaljohn AL; Welkos SL; Smith LA; Smith JF Vaccine; 2006 Nov; 24(47-48):6886-92. PubMed ID: 16828936 [TBL] [Abstract][Full Text] [Related]
5. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Pushko P; Bray M; Ludwig GV; Parker M; Schmaljohn A; Sanchez A; Jahrling PB; Smith JF Vaccine; 2000 Aug; 19(1):142-53. PubMed ID: 10924796 [TBL] [Abstract][Full Text] [Related]
6. Complex adenovirus-vectored vaccine protects guinea pigs from three strains of Marburg virus challenges. Wang D; Hevey M; Juompan LY; Trubey CM; Raja NU; Deitz SB; Woraratanadharm J; Luo M; Yu H; Swain BM; Moore KM; Dong JY Virology; 2006 Sep; 353(2):324-32. PubMed ID: 16820184 [TBL] [Abstract][Full Text] [Related]
7. Evaluation in nonhuman primates of vaccines against Ebola virus. Geisbert TW; Pushko P; Anderson K; Smith J; Davis KJ; Jahrling PB Emerg Infect Dis; 2002 May; 8(5):503-7. PubMed ID: 11996686 [TBL] [Abstract][Full Text] [Related]
8. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Swenson DL; Warfield KL; Negley DL; Schmaljohn A; Aman MJ; Bavari S Vaccine; 2005 Apr; 23(23):3033-42. PubMed ID: 15811650 [TBL] [Abstract][Full Text] [Related]
9. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Wilson JA; Bray M; Bakken R; Hart MK Virology; 2001 Aug; 286(2):384-90. PubMed ID: 11485406 [TBL] [Abstract][Full Text] [Related]
10. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. Pushko P; Geisbert J; Parker M; Jahrling P; Smith J J Virol; 2001 Dec; 75(23):11677-85. PubMed ID: 11689649 [TBL] [Abstract][Full Text] [Related]
11. De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses. Wang D; Schmaljohn AL; Raja NU; Trubey CM; Juompan LY; Luo M; Deitz SB; Yu H; Woraratanadharm J; Holman DH; Moore KM; Swain BM; Pratt WD; Dong JY Vaccine; 2006 Apr; 24(15):2975-86. PubMed ID: 16530297 [TBL] [Abstract][Full Text] [Related]
12. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Hevey M; Negley D; Geisbert J; Jahrling P; Schmaljohn A Virology; 1997 Dec; 239(1):206-16. PubMed ID: 9426460 [TBL] [Abstract][Full Text] [Related]